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Autosomal dominant mutations that activate the leucine-rich
repeat kinase 2 (LRRK2) cause inherited Parkinson’s disease.
Recent work has revealed that LRRK2 directly phosphorylates
a conserved threonine/serine residue in the effector-binding
switch-II motif of a number of Rab GTPase proteins, including
Rab10. Here we describe a facile and robust method to assess
phosphorylation of endogenous Rab10 in mouse embryonic
fibroblasts (MEFs), lung and spleen-derived B-cells, based on
the ability of the Phos-tag reagent to retard the electrophoretic
mobility of LRRK2-phosphorylated Rab10. We exploit this assay
to show that phosphorylation of Rab10 is ablated in kinase-
inactive LRRK2[D2017A] knockin MEFs and mouse lung,
demonstrating that LRRK2 is the major Rab10 kinase in these
cells/tissue. We also establish that the Phos-tag assay can be
deployed to monitor the impact that activating LRRK2 pathogenic
(G2019S and R1441G) knockin mutations have on stimulating
Rab10 phosphorylation. We show that upon addition of LRRK2
inhibitors, Rab10 is dephosphorylated within 1–2 min, markedly
more rapidly than the Ser935 and Ser1292 biomarker sites that
require 40–80 min. Furthermore, we find that phosphorylation of
Rab10 is suppressed in LRRK2[S910A + S935A] knockin MEFs
indicating that phosphorylation of Ser910 and Ser935 and potentially
14-3-3 binding play a role in facilitating the phosphorylation
of Rab10 by LRRK2 in vivo. The Rab Phos-tag assay has
the potential to significantly aid with evaluating the effect that
inhibitors, mutations and other factors have on the LRRK2
signalling pathway.
Key words: Parkinson’s disease, protein kinases, Rab GTPase,
signal transduction.
INTRODUCTION
Our knowledge of the origins of Parkinson’s disease has been
transformed by the identification of genes whose mutation in
humans leads to Mendelian inherited disease [1,2]. One of these
genes encodes the leucine-rich repeat kinase 2 (LRRK2) protein
kinase where autosomal dominant mutations account for ∼1%
of sporadic Parkinson’s disease [3,4]. The most common LRRK2
mutation converts Gly2019 into a serine within the kinase domain
magnesium ion-binding motif [5]. This mutation enhances in vitro
protein kinase activity ∼3-fold [6,7], indicating that abnormal
increase in the kinase activity of LRRK2 is involved in the
pathogenesis of Parkinson’s disease, suggesting that LRRK2
kinase inhibitors have therapeutic benefit for the treatment of
Parkinson’s disease. LRRK2 is a large enzyme (2527 residues),
consisting of leucine-rich repeats (residues 1010–1287), a GTPase
domain (residues 1335–1504), a COR [C-terminal of ROC (Ras
of complex GTPase domain)] domain (residues 1517–1843), a
serine/threonine protein kinase domain (residues 1875–2132)
and a WD40 repeat (residues 2231–2276) [8]. Three well-
characterized pathogenic mutations occur within the GTPase
domain (R1441C, R1441G and R1441H) [9,10] and one within
the COR domain (Y1699C) [11]. Unlike the G2019S mutation,
the R1441G/H/C and Y1699C mutations do not directly enhance
LRRK2 in vitro kinase activity [12].
We recently reported that members of the Rab GTPase family,
including Rab8A and Rab10 were direct physiological substrates
for LRRK2 [13]. The LRRK2 phosphorylation site (Thr72 for
Rab8A and Thr73 for Rab10) is conserved in ∼50 different Rab
proteins [13], and lies within the effector-binding switch-II motif
[14–16]. LRRK2 phosphorylation of Rab8A and Rab10 proteins
is inhibitory as it suppresses binding to the Rab GDP-dissociation
inhibitor (GDI) factors that are required for membrane delivery
and recycling [13]. Furthermore, LRRK2 phosphorylation also
inhibits binding of Rab8A to Rabin-8, its guanine-nucleotide-
exchange factor (GEF) activator [13].
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Other work has also linked Rab GTPases with Parkinson’s
disease. For example, Rab7L1 (also known as Rab29) is one
of five genes that is mutated with Parkinson’s disease patients
that have the PARK16 mutation [17,18]. Depletion of Rab7L1
reportedly induced loss of dopaminergic neurons, similar to that
observed with LRRK2-[G2019S] expression [19]. Furthermore,
genetic analysis has recently revealed that loss of function
mutations in the poorly studied Rab39B protein is responsible for
a rare form of X-linked Parkinson’s disease [20,21]. Moreover,
overexpression of Rab8a, Rab1 and Rab3a protein attenuated
α-synuclein-induced cytotoxicity in cellular and animal models
of Parkinson’s disease [22,23]. Finally, another protein kinase
mutated in Parkinson’s disease termed PINK1, indirectly controls
the phosphorylation of a small group of Rabs including Rab8A
at a site distinct from that used by LRRK2 (Ser111 on Rab8A)
[24]. Taken together these results strongly suggest a functional
interplay between Rab GTPases and known Parkinson’s disease
factors.
In 2004, an agent (1,3-bis[bis(pyridin-2-ylmethyl)
amino]propan-2-olato dizinc(II) complex) commonly referred to
as ‘Phos-tag’ was described that binds to phosphate ions with
much higher affinity (Kd ∼ 25 nM for phenyl phosphate) than
other anions [25]. The Phos-tag reagent was subsequently shown
to interact with high affinity with proteins as well as peptides
phosphorylated on serine, threonine and tyrosine residues [26].
A modified version of the Phos-tag reagent termed ‘Phos-tag
acrylamide’ (N-(5-(2-acryloylaminoethylcarbamoyl)pyridin-2-
ylmethyl)-N,N ′,N ′-tris(pyridin-2-yl-methyl)-1,3-diaminopropan-
2-ol) was developed that when polymerized into SDS/
polyacrylamide gels retarded electrophoretic mobility of
phosphorylated proteins, resulting in substantial mobility shifts
[27]. The Phos-tag approach is particularly suited for analysing
phosphorylation of relatively small proteins such as Rab protein
that are phosphorylated at a single site. We previously observed
that in a human embryonic kidney (HEK)-293 cell overexpression
system, LRRK2 phosphorylation of haemagglutinin (HA)–
Rab8A and HA–Rab10 resulted in an electrophoretic mobility
shift of the phosphorylated Rab protein [13]. We also observed
that pathogenic LRRK2 mutations tested, including the R1441G,
Y1699C and G2019S, stimulated phosphorylation of Rab protein
to a greater extent than wild-type (WT) LRRK2 [13].
An important goal is to develop robust methods to rapidly
assess LRRK2 phosphorylation of endogenous Rab proteins in
samples where sample material may be limiting. In the present
study we develop a straightforward procedure based on the
Phos-tag approach to quantitatively assess phosphorylation of
endogenous Rab10 in mouse embryonic fibroblasts (MEFs),
lung tissue as well as spleen-derived B-cells. We demonstrate
that ablation of LRRK2 catalytic activity in a novel kinase-
inactive LRRK2[D2017A] knockin mouse model blocks Rab10
phosphorylation in MEFs as well as lung, demonstrating that
LRRK2 is indeed the major Rab10 kinase in these cells and
tissue. We establish that the Phos-tag assay can be used to monitor
the impact of LRRK2 inhibitors, as well as pathogenic knockin
mutations (G2019S and R1441G) on Rab10 phosphorylation.
There is also significant interest in studying the roles that LRRK2
Ser910 and Ser935 phosphorylation play, as phosphorylation of these
residues promotes 14-3-3 binding and LRRK2 inhibitors induce
their dephosphorylation [12,28]. To address whether Ser910 and
Ser935 play a role in regulating Rab10 phosphorylation in vivo, we
generated LRRK2[S910A + S935A] knockin MEFs and found
that this mutation significantly inhibits Rab10 phosphorylation.
The Rab10 Phos-tag assay will aid assessment of the impact
that inhibitors, mutations and other factors have on the LRRK2
signalling pathway.
MATERIALS AND METHODS
Reagents
GSK2578215A was obtained from GlaxoSmithKline [29]. HG-
10-102-01 was custom synthesized as described previously [30].
MLi-2 was obtained from Merck and also synthesized as described
in [31a]. Phos-tag acrylamide was synthesized as described in
[31b]. Phos-tag acrylamide was stored at 5 mM aqueous solution
(3.43 mg of compound in 1 ml of solution) at 4 ◦C in black tubes
that block out light as Phos-tag acrylamide is light-sensitive.
HPLC analysis of stock Phos-tag acrylamide was undertaken
every 4–5 weeks to ensure stock had not started to polymerize. All
recombinant proteins, DNA constructs and antibodies generated
for the present study can be requested via our reagents website
(https://mrcppureagents.dundee.ac.uk/).
General methods
DNA procedures were undertaken using standard protocols. DNA
constructs were purified from E. coli DH5α using a Maxi Prep
kit (Qiagen). DNA sequence of the DNA constructs used in
the present study was performed by our Sequencing Service
(http://www.dnaseq.co.uk).
Antibodies
Anti-Rab10 antibody was from Cell Signaling Technology
(#8127) and used at 1:1000 dilution. Rabbit monoclonal
antibodies for total LRRK2 (UDD3) and pS935-LRRK2 (UDD2)
were purified at the University of Dundee and used at 1:10000
and 1:2000 dilutions respectively. Rabbit monoclonal antibody
detecting phospho-Ser1292 LRRK2 was from Abcam (ab203181)
and used at a final concentration of 1 μg/ml. Anti-glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) antibody was from Santa
Cruz Biotechnology (sc-32233) and used at 1:5000 dilution.
Sheep polyclonal antibody for phospho-Thr73 Rab10 (S873D)
was described previously [13] and used at final concentration of
1 μg/ml in the presence of 10 μg/ml non-phosphorylated peptide.
Horseradish peroxidase-conjugated anti-mouse (#31450), -rabbit
(#31460), -rat (#31470) and -sheep IgG secondary antibodies
(#31480) were from Thermo Fisher Scientific.
Plasmids
The following constructs were used for protein production:
6His-SUMO-Rab10 WT (DU51062), 6His-SUMO-Rab8A WT
(DU47363). The following constructs were used for overex-
pression in cells: HA–Rab10 WT/T73A (DU44250/DU51006),
FLAG–LRRK2 R1441G (DU13077). The following constructs
were used for generation of Rab10 knockout (KO) A549
cells: Rab10 KO N-terminal antisense guide and Cas9
D10A (DU52110) and Rab10 KO N-terminal sense guide
(DU52100). Full datasheets for each plasmid are available from
https://mrcppureagents.dundee.ac.uk/.
Mice
All animal studies were ethically reviewed and carried out in
accordance with Animals (Scientific Procedures) Act 1986, the
GSK Policy on the Care, Welfare and Treatment of Animals,
regulations set by the University of Dundee and the U.K. Home
Office. Animal studies and breeding were approved by the
University of Dundee ethical committee and performed under a
c© 2016 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution Licence 4.0 (CC BY).
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U.K. Home Office project licence and maintained under specific
pathogen-free conditions at the University of Dundee. Animals
(unless otherwise stated) were multiply housed at an ambient
temperature (20–24 ◦C) and humidity (45–55%) maintained on a
12 h light/12 h dark cycle, with free access to food (SDS RM No.
3 autoclavable) and water.
The LRRK2[G2019S]GSK knockin mice, the LRRK2[A2016T]
knockin mice and the LRRK2[R1441G] knockin mice were
described previously [13,32]. The LRRK2 KO mice were
generated and provided by Dr Huaibin Cai (National Institutes
of Health, Bethesda, MD, U.S.A.) and have been described
previously [33].
For experiments shown in Figures 5(B) and 7, littermate
matched WT and LRRK2 knockin mice (3–6 months of age)
were injected subcutaneously either with vehicle [40% (w/v)
(2-hydroxypropyl)-β-cyclodextrin (Sigma–Aldrich)] or MLi-2
dissolved in vehicle at the indicated dose and killed by cervical
dislocation 1 h after treatment. Lung was rapidly isolated and snap
frozen in liquid nitrogen. No specific randomization method or
blinding was applied to experiments.
Generation of LRRK2[D2017A] knockin mice
The LRRK2[D2017A] knockin mouse line was generated by a
targeting strategy devised to introduce the point mutation D2017A
into exon 41 of the LRRK2 gene by homologous recombination
in mouse embryonic stem (ES) cells. 5′ and 3′ homology arms
(approximately 4.8 and 3.8 kb respectively) flanking exon 41
were generated using Phusion High-Fidelity DNA Polymerase
(New England Biolabs) on a C57BL/6J genomic DNA template.
Similarly, a 739 bp fragment carrying exon 41 lying between these
two homology arms was isolated and subjected to site-directed
mutagenesis with the QuikChangeII site-directed mutagenesis
kit (Stratagene) to introduce the appropriate point mutation (A
to C mutation at bp 102 of exon 41). The 5′ and 3′ homology
arms and the mutated exon 41 fragments were subcloned into
a parental targeting vector to achieve the positioning of the
loxP and FRT sites and PGKneo cassette. Gene targeting was
performed in de novo generated hybrid C57BL/6J;129Ola-derived
ES cells. The targeting construct was linearized and electroporated
into ES cells according to standard methods. ES cells correctly
targeted at the 3′ end was identified by Southern blot analysis
of EcoRV digested genomic DNA using a PCR-derived external
probe. Correct gene targeting at the 5′ end and presence of the
point mutation was confirmed by sequencing of a ∼6 kb PCR
product. The latter was generated by high-fidelity PCR of ES
cell clone-derived genomic DNA using primers spanning the 5′
homology arm. Correctly targeted ES cell clones were injected
into BALB/c blastocysts and implanted into foster mothers
according to standard procedures. Male chimaeras resulting
from the D2017A-targeted ES cells were bred with C57BL/6J
female mice expressing CRE recombinase from the ROSA26
locus to facilitate removal of the loxP flanked PGKneo cassette
in vivo, and germline transmission of the targeted allele was
confirmed by PCR. Germline mice were back-crossed once
to C57BL/6J mice, and confirmed to be >98% C57BL/6J
by single nucleotide polymorphism (SNP) analysis. The line
was subsequently maintained by breeding with C57BL/6J, and
crossing mice heterozygous for the point mutation generated
homozygous mice at the expected Mendelian ratio. Separate
colonies of WT and homozygous animals were subsequently
maintained to minimize breeding wastage. Standard genotyping
which distinguishes WT from point mutation knockin alleles was
used throughout. Genotyping of mice was performed by PCR
using genomic DNA isolated from ear biopsies.
Generation of LRRK2[S910A+S935A] knockin mice
The constitutive LRRK2[S910A + S935A] knockin mouse line
was produced by implementing a targeting strategy based on
NCBI transcript NM_025730.3, to introduce two point mutations
S910A and S935A into exon 21 of the LRRK2 gene by
homologous recombination in mouse ES cells (TaconicArtemis).
To start with, the S910A and S935A mutations have been
introduced into exon 21 by site-directed mutagenesis with the
QuikChangeII site-directed mutagenesis kit (Stratagene) (S910A:
TCA to GCC and S935A: TCG to GCG of exon 21). The positive
selection marker PuroR has been flanked by FRT sites and inserted
into intron 21. 5′ and 3′ homology arms (approximately 4.1
and 6 kb respectively) flanking exon 21 were generated using
Phusion High-Fidelity DNA Polymerase (New England Biolabs)
on a C57BL/6J genomic DNA template. The 5′ and 3′ homology
arms comprising mutated exon 21 were subcloned into a parental
targeting vector to achieve the positioning of the loxP and FRT
sites and PGKneo cassette. For this purpose, the targeting vector
was generated using bacterial artificial chromosome (BAC) clones
from the C57BL/6J RPCIB-731 BAC library which then were
transfected into the TaconicArtemis C57BL/6N Tac ES cell line.
Homologous recombinant clones were selected using positive
(PuroR) and negative (thymidine kinase – Tk) selection. The
constitutive knockin allele comprising desired mutations was
obtained after Flp-mediated removal of the selection marker. The
targeting construct was linearized and electroporated into ES cells
according to standard methods. Successful gene targeting of ES
cells at the 5′ and 3′ ends was confirmed by sequencing of a ∼6 kb
PCR product. Properly targeted ES cell clones were then subjected
to the diploid injection into BALB/c blastocysts and implanted
into foster mothers according to standard procedures. Male
chimaeras resulting from the LRRK2[S910A + S935A]-targeted
ES cells were bred with C57BL/6J female mice expressing Cre
recombinase from the ROSA26 locus to facilitate removal of the
loxP flanked PGKneo cassette in vivo, and germline transmission
was identified by the presence of black, strain C57BL/6, offspring
(G1) and PCR.
Genotyping of mice
For LRRK2[D2017A] knockin mice, primers 5′-CCGAG-
CCAAAAACTAAGCTC-3′ and 5′-CCATCTTGGGTACTT-
GACC-3′ were used to detect the WT and knockin alleles
(WT, 400 bp; knockin, 550 bp; heteroduplex formation). For
LRRK2[S910A + S935A] knockin mice, primers 5′-GTG-
CTTGAAGTTTGATCATAATGC-3′ and 5′-GCATATAGCA-
TGTAGTGTCATCTCC-3′ were used to detect the WT and
knockin alleles (WT, 326 bp; knockin, 401 bp; heteroduplex
formation). The PCR programme consisted of 5 min at 95 ◦C,
then 35 cycles of 30 s at 95 ◦C, 30 s at 60 ◦C and 30 s at 72 ◦C,
and then 5 min at 72 ◦C. DNA sequencing was used to confirm
the knockin mutation and performed by DNA Sequencing
& Services (MRC-PPU; http://www.dnaseq.co.uk/) using
Applied Biosystems Big-Dye version 3.1 chemistry on Applied
Biosystems model 3730 automated capillary DNA sequencer.
Generation and culture of MEFs
Littermate matched WT and homozygous
LRRK2[S910A + S935A] or homozygous LRRK2[R1441G]
c© 2016 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution Licence 4.0 (CC BY).
2674 G. Ito and others
knockin MEFs were isolated from mouse embryos at embryonic
day (E)12.5 resulting from crosses between heterozygous
LRRK2[S910A + S935A]/WT or LRRK2[R1441G]/WT
mice using a previously described protocol [34].
LRRK2[S910A + S935A] cells were genotyped as described
above and LRRK2[R1441G] cells were genotyped as described
previously [32]. Homozygous LRRK2[S910A + S935A] knockin
as well as the WT cells generated from the same littermate
were spontaneously immortalized by prolonged passaging in
parallel for at least 20 passages before being used for Phos-tag
experiments. Genotype of these cells was also confirmed
by immunoblot analysis with anti-phospho-Ser910 and -Ser935
antibodies (Figure 8A). Homozygous LRRK2[R1441G] knockin
MEFs used for the experiment shown in Figure 6(A) were used
on passage 5.
Littermate matched WT and homozygous LRRK2[D2017A]
knockin MEFs were isolated by Dr Francisco Inesta-Vaquera
(University of Dundee) from mouse embryos at E12.5 resulting
from crosses between heterozygous LRRK2[D2017A]/WT mice
using a previously described protocol [34]. Cells were genotyped
as described above for mice, and WT and homozygous
LRRK2[D2017A] knockin cells generated from the same
littermate were selected for subsequent experiments. Cells were
continuously passaged in parallel for at least 20 passages before
being used for Phos-tag experiments. An identical approach was
used to generate littermate WT and LRRK2[S910A + S935A]
and LRRK2[R1441G] knockin MEFs.
Littermate matched WT and homozygous LRRK2[G2019S]GSK
MEFs, littermate matched WT and homozygous
LRRK2[A2016T] MEFs and littermate matched WT and
homozygous LRRK2 KO MEFs were isolated as described
previously and used at over passage 20 [13,35].
All MEFs were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) containing 10% FBS, 2 mM L-glutamine,
100 units/ml penicillin, 100 μg/ml streptomycin, non-essential
amino acids (Life Technologies) and 1 mM sodium pyruvate (Life
Technologies). All knockin and KO cell lines were verified by
allelic sequencing.
Mouse tissue lysate preparation
Frozen mouse tissues were quickly defrosted in the ice-cold
lysis buffer containing 50 mM Tris/HCl, pH 7.5, 1% (v/v)
Triton X-100, 1 mM EGTA, 1 mM sodium orthovanadate, 50 mM
NaF, 0.1% (v/v) 2-mercaptoethanol, 10 mM 2-glycerophosphate,
5 mM sodium pyrophosphate, 0.1 μg/ml mycrocystin-LR (Enzo
Life Sciences), 270 mM sucrose and Complete EDTA-free
protease inhibitor cocktail (Roche) and homogenized using
a POLYTRON homogenizer (KINEMATICA) on ice (5 s
homogenization, 10 s interval and 5 s homogenization). Lysates
were centrifuged at 20800 g for 30 min at 4 ◦C and supernatants
were used for Bradford assay and immunoblot analysis.
Generation of Rab10 KO A549 cells
A549 cells at ∼80% confluency were co-transfected in a six-well
plate with DU52110 and DU52100 plasmids using Lipofectamine
LTX (Life Technologies) according to the manufacturer’s
instructions, with a final amount of 9 μl of Lipofectamine LTX
and 2.5 μg of DNA per well. The cells were then incubated
for 24 h in DMEM supplemented with 10% FBS, 2 mM L-
glutamine, 100 units/ml penicillin and 100 μg/ml streptomycin.
The medium was then replaced with fresh medium supplemented
with 2 μg/ml puromycin. After 24 h of puromycin selection
the medium was replaced again with fresh medium without
puromycin and the cells were left to recover for 48 h before
performing single-cell sorting. Cell sorting was performed using
influx cell sorter (Becton Dickinson). Single cells were placed
in individual wells of a 96-well plate containing DMEM
supplemented with 10% FBS, 2 mM L-glutamine, 100 units/ml
penicillin, 100 μg/ml streptomycin and 100 μg/ml Normocin
(InvivoGen). After reaching ∼80% confluency individual clones
were transferred into six-well plates. After reaching ∼80%
confluency the clones were screened by Western blotting for
the presence of Rab10. Selected clones lacking expression of
Rab10 were sequenced to confirm the KO. Genomic DNA was
isolated using a GenElute Mammalian Genomic DNA Miniprep
Kit (Sigma–Aldrich). The PCR was performed using PfuUltra
High-Fidelity DNA Polymerase (Agilent Technologies) with
primers 5′-TTCCTCAAAGCTGTTCGTAGGTCG-3′ and 5′-
TCCTCCCACAGGTCTTACCTATGG-3′ to amplify the region
targeted for KO, followed by incubation with Taq polymerase
(New England Biolabs) to add 3′ A overhangs. The PCR
products were then cloned into pSC-A-amp/kan vector using
StrataClone PCR Cloning Kit (Agilent Technologies). For each
cloning reaction 20 positive bacterial colonies were selected and
the plasmids were isolated using QIAprep Spin Miniprep Kit
(Qiagen). The inserts in each individual clone were sequenced
using M13 primers (DNA sequencing facility of Division of
Signal Transduction Therapy at the University of Dundee). This
procedure allowed us to confirm that there were no WT alleles
of the Rab10 gene present in the genome of selected clone thus
confirming a successful KO.
Cell culture, transfection, treatments and lysis
HEK-293 and A549 cells were maintained in DMEM containing
10% (v/v) FBS, 2 mM L-glutamine, 100 units/ml penicillin and
100 μg/ml streptomycin at 37 ◦C in a humidified atmosphere
with 5% CO2. HEK-293 cells were seeded into six-well
plates at 3×105 cells/well, and after 24 h culture cells were
transfected with Lipofectamine 2000 (Life Technologies) using
0.5 μg of the Rab10 plasmid, 2 μg of the LRRK2 plasmid and
6 μl of Lipofectamine 2000 according to the manufacturer’s
protocol. Cells were lysed 24 h after transfection. Inhibitors
were dissolved in DMSO. An equivalent volume of DMSO
was added to negative control samples. Following treatment,
cells were washed with TBS (20 mM Tris/HCl, pH 7.5, and
150 mM NaCl) on ice and lysed in an ice-cold lysis buffer
containing 50 mM Tris/HCl, pH 7.5, 1% (v/v) Triton X-100,
1 mM EGTA, 1 mM sodium orthovanadate, 50 mM NaF, 0.1%
(v/v) 2-mercaptoethanol, 10 mM 2-glycerophosphate, 5 mM
sodium pyrophosphate, 0.1 μg/ml mycrocystin-LR (Enzo Life
Sciences), 270 mM sucrose and Complete EDTA-free protease
inhibitor cocktail (Roche). Lysates were centrifuged at 20800 g
for 15 min at 4 ◦C and supernatants were used for Bradford assay
(Thermo Scientific) and immunoblot analysis.
Phos-tag SDS/PAGE and immunoblot analysis
Cell/tissue lysates were mixed with 4× SDS/PAGE sample
buffer [250 mM Tris/HCl, pH 6.8, 8% (w/v) SDS, 40% (v/v)
glycerol, 0.02% (w/v) Bromophenol Blue and 4% (v/v) 2-
mercaptoethanol] and heated at 95 ◦C for 5 min. For normal
SDS/PAGE, 10–20 μg samples were loaded on to NuPAGE Bis-
Tris 4–12% gels (Life Technologies) and electrophoresed at
150 V. For Phos-tag SDS/PAGE, samples were supplemented
with 10 mM MnCl2 before loading gels. Phos-tag SDS/PAGE
c© 2016 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution Licence 4.0 (CC BY).
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was carried out essentially as described previously [27]. Gels
for Phos-tag SDS/PAGE consisted of a stacking gel [4%
(w/v) acrylamide, 125 mM Tris/HCl, pH 6.8, 0.1% (w/v) SDS,
0.2% (v/v) N,N,N′,N′ tetramethylethylenediamine (TEMED) and
0.08% (w/v) ammonium persulfate (APS)] and a separating
gel [12% (w/v) acrylamide, 375 mM Tris/HCl, pH 8.8, 0.1%
(w/v) SDS, 75 μM Phos-tag acrylamide, 150 μM MnCl2, 0.1%
(v/v) TEMED and 0.05% (w/v) APS]. The gel mixture was
degassed for 10 min before adding TEMED and APS. After
centrifugation at 20800 g for 1 min, 10–30 μg samples were
loaded and electrophoresed at 70 V for the stacking part and
at 150 V for the separating part with the running buffer
[25 mM Tris/HCl, 192 mM glycine and 0.1% (w/v) SDS].
For Coomassie Blue staining, gels were stained with Colloidal
Coomassie Blue Staining Kit (Life Technologies) according to
the manufacturer’s instructions. For immunoblot analysis, gels
were washed for 10 min in the transfer buffer [48 mM Tris/HCl,
39 mM glycine and 20% (v/v) methanol] containing 10 mM
EDTA and 0.05% (w/v) SDS three times, followed by one
wash in the transfer buffer containing 0.05% SDS for 10 min.
Proteins were electrophoretically transferred onto nitrocellulose
membranes (Amersham Protran 0.45 μm NC; GE Healthcare)
at 100 V for 180 min on ice in the transfer buffer without
SDS/EDTA. Transferred membranes were blocked with 5%
(w/v) non-fat dry milk (NFDM) dissolved in TBS-T [20 mM
Tris/HCl, pH 7.5, 150 mM NaCl and 0.1% (v/v) Tween 20] at
room temperature for 30 min. Membranes were then incubated
with primary antibodies diluted in 5% NFDM and skim milk
powder in TBS-T overnight at 4 ◦C. After washing membranes in
TBS-T, membranes were incubated with horseradish peroxidase-
labelled secondary antibodies diluted in 5% NFDM and skim
milk powder in TBS-T at room temperature for 1 h. After
washing membranes in TBS-T, protein bands were detected
by exposing films [Medical Film (Konica Minolta) for normal
immunoblot and Amersham Hyperfilm ECL (GE Healthcare)
for Phos-tag immunoblot] to the membranes using an ECL
solution [Amersham ECL Western Blotting Detection Reagents
(GE Healthcare) for normal immunoblot and SuperSignal West
Dura Extended Duration (Thermo Fisher Scientific) for Phos-tag
immunoblot].
Purification of Rab proteins
Rab10
The coding sequence for human Rab10 (accession number:
NM_016131.4) was cloned into pET15b so that the protein
was N-terminally tagged with 6His-SUMO (clone number
DU51062). BL21(DE3) cells were co-transformed with pET15b-
6His-SUMO-Rab10 and a plasmid encoding the chaperone
GroEL/S, and clones were allowed to grow in the presence
of 100 μg/ml carbenicillin and 20 μg/ml chloramphenicol.
Transformed bacteria were grown overnight and used to inoculate
6 litres of LB containing 50 μg/ml carbenicillin and 20 μg/ml
chloramphenicol. After growing cells to a D600 of 0.4 at 37 ◦C,
temperature was lowered to 16 ◦C and cells were grown until
reaching a D600 of 0.6. Expression of Rab10 was induced
by adding 125 μM IPTG for 14–18 h at 16 ◦C with agitation
at 200 rotations/min. Cells were collected by sedimentation
and resuspended in ice-cold 50 mM Tris/HCl, pH 7.5, 250 mM
NaCl, 0.2% Triton X-100, 5 mM MgCl2, 10 μM GDP, 1 mM
tris-(2-carboxyethyl)phosphine (TCEP), 1 μM Pefabloc and
0.1% leupeptin. The suspension was sonicated and insoluble
material was removed by centrifugation (20 min at 40000 g).
The supernatant was supplemented with 10% glycerol, 20 mM
imidazole, 50 μM ATP and 1 ml Ni-agarose and incubated on
a roller mixer for 1 h at 4 ◦C. Contaminants were removed with
five washes (5 × 12 vol.) of 50 mM Tris/HCl, pH 7.5, 250 mM
NaCl, 10% glycerol, 25 mM imidazole, 5 mM MgCl2, 0.2%
Triton X-100, 0.03% Brij-35, 10 μM GDP, 50 μM ATP and
1 mM TCEP. Rab10 was removed from the resin by cleaving
the His-SUMO tag using 1 mg of a catalytic domain of SUMO-
specific protease His-SENP1 (amino acids 415–643) for 16 h at
4 ◦C and collected in four resin volumes. The protein was diluted
10-fold into 50 mM HEPES/NaOH, pH 7.5, 25 mM NaCl, 10%
glycerol, 5 mM MgCl2, 0.03%Brij-35, 10 μM GDP, 50 μM ATP
and 1 mM TCEP and purified further over a 1 ml heparin HiTrap
HP column (GE Healthcare), which was developed with a total
18 ml gradient of NaCl (25–1200 mM). Rab10 was eluted in two
peaks, of which the earlier peak, eluting at approximately 200 mM
NaCl, contained 90% pure Rab10. The yield is very low at only
50 μg/l expression.
Rab8A
The coding sequence for human Rab8A (accession number:
NM_005370.4) was cloned into pET15b (clone number
DU47363) and purified as described previously [13].
Assessment of kinase activity of endogenous LRRK2
In Figure 2(B), the kinase activity of endogenous LRRK2
immunoprecipitated from littermate WT and kinase-inactive
LRRK2[D2017A] knockin MEFs was assessed in an in vitro
kinase reaction as previously described [35]. Briefly, endogenous
LRRK2 was immunoprecipitated from lysates (5 mg of protein)
using 10 μg of anti-LRRK2 antibody UDD3 coupled to Protein
A–Sepharose beads. A control was also included when UDD3
was replaced by pre-immune IgG. Peptide kinase assays were
set up with immunoprecipitated LRRK2 in 50 mM Tris/HCl
(pH 7.5), 0.1 mM EGTA, 10 mM MgCl2 and 0.1 mM [γ -32P]ATP
(∼300–500 c.p.m./pmol, PerkinElmer) in the presence of 20 μM
Nictide peptide substrate (RLGWWRFYTLRRARQGNTKQR)
in the presence of either 1 μM MLi-2 or the equivalent
volume of DMSO. After incubation for 20 min at 30 ◦C with
shaking, reactions were terminated by applying the reaction
mixture on to P81 phosphocellulose papers and immersing
in 50 mM orthophosphoric acid. After extensive washing,
reaction products were quantified by Cerenkov counting.
For experiments performed in Figure 7(B), the endogenous
LRRK2 was immunoprecipitated from littermate WT and
LRRK2[S910A + S935A] knockin MEFs as described above.
Kinase assays were carried out using purified Rab8A protein as a
substrate as described previously [13].
Assessment of phosphorylation at Ser1292 of endogenous LRRK2
Endogenous LRRK2 was immunoprecipitated as described above
from lysates (3.5 mg of protein). Immunoprecipitated LRRK2
was washed twice with the lysis buffer containing 0.5 M NaCl
and eluted from the beads with 30 μl of 2× NuPAGE lithium
dodecyl sulfate (LDS) Sample Buffer (Thermo Fisher Scientific).
Eluted samples at 5 and 15 μl were loaded for detecting total
LRRK2 and phospho-Ser1292 LRRK2 respectively. For detecting
phospho-Ser1292 LRRK2 VeriBlot secondary antibody (Abcam,
ab131366) was used instead of normal anti-rabbit IgG secondary
antibody.
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Figure 1 Phos-tag analysis of LRRK2 mediated Rab10 phosphorylation
(A) Time course of LRRK2-mediated phosphorylation of recombinant Rab10, in the absence or presence of the LRRK2 inhibitor MLi-2. Rab10 phosphorylation was analysed by a Phos-tag assay
using an anti-total Rab10 antibody or a phospho-specific antibody. A Coomassie Blue-stained Phos-tag gel is also shown (top panel). Control immunoblots (Rab10 total and LRRK2) were done on
normal gels using the indicated antibodies (bottom panels). (B) HEK-293 cells were transfected with FLAG–LRRK2 R1441G and HA–Rab10 WT or T73A mutant and treated with or without 100 nM
MLi-2 for 1 h. Phosphorylation of overexpressed Rab10 was analysed by a Phos-tag assay (top panel). Equal levels of expression of HA–Rab10 and FLAG–LRRK2 R1441G were confirmed by
immunoblotting on normal gels using an anti-HA (second panel from the top) and anti-LRRK2 (third panel from the top) antibodies respectively. Equal loading was shown by immunoblotting with
an anti-GAPDH antibody (bottom panel). Bands corresponding to phosphorylated and non-phosphorylated Rab10 were marked with open () and closed () circles respectively. Similar results
were obtained in at least two separate experiments.
In vitro phosphorylation of Rab10 by LRRK2
Purified Rab10 (6.5 μg per 25 μl reaction) was phosphorylated
using full-length LRRK2[G2019S] (0.8 μg) in a buffer containing
50 mM Tris/HCl, pH 7.5, 0.1 mM EGTA, 10 mM MgCl2 and
1 mM ATP, in the absence or presence of the LRRK2 inhibitor
MLi-2 (1 μM final concentration). A reaction where no LRRK2
was added was also included as a negative control. Assays were
carried out in Dispo-Biodialysers of 1 kDa molecular mass cut-
off (Sigma–Aldrich) put in 0.5 litre of the same buffer to allow
for ADP exchange for the indicated times at room temperature.
Kinase reactions were terminated by addition of sample buffer
containing 2-mercaptoethanol.
Isolation of B-cells from mouse spleen
Mouse B-cells were isolated from spleen using the MACSTM B-
Cell Isolation Kit (Miltenyi Biotec, catalogue number 130-090-
862) according to manufacturer’s instructions. After isolation,
B-cells were cultured in RPMI 1640 medium supplemented
with 10% heat-inactivated FBS, 2 mM L-glutamine, 50 units/ml
penicillin, 50 μg/ml streptomycin, sodium pyruvate and non-
essential amino acids (Life Technologies) for 90 min before
being treated with the LRRK2 inhibitor MLi-2 (50 nM final
concentration) for 60 min.
RESULTS
Validation of the Phos-tag approach to assess LRRK2-mediated
phosphorylation of Rab10
We first explored the effect of phosphorylation of recombinant
bacterial expressed Rab10 with LRRK2[G2019S] on the
electrophoretic mobility of Rab10 on Phos-tag-containing
polyacrylamide gels. LRRK2 phosphorylation induced a time-
dependent retardation in the migration of phosphorylated Rab10,
an effect that was prevented by inclusion of the MLi-2
LRRK2 kinase inhibitor in the kinase reaction [36] (Figure 1A).
Immunoblot analysis with a phospho-specific antibody confirmed
that the slower migrating Rab10 species that appears following
LRRK2 phosphorylation is indeed Rab10 phosphorylated at Thr73
(Figure 1A). We also studied LRRK2-mediated phosphorylation
of HA–Rab10 following its co-expression with pathogenic
LRRK2[R1441G] in HEK-293 cells. Under these conditions
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Figure 2 Phosphorylation of endogenous Rab10 in MEFs analysed by Phos-tag assay
(A) WT MEFs were treated with 0.1 % (v/v) DMSO ( − ), 1 μM GSK2578215A (GSK), 3 μM HG-10-102-01 (HG) or 10 nM MLi-2 for 1 h in duplicate. Cell lysates were prepared and Rab10
phosphorylation was analysed by a Phos-tag assay (top panel). Control immunoblots were done on normal gels with the indicated antibodies. (B) LRRK2 immunoprecipitated from littermate WT
or kinase-inactive LRRK2[D2017A] knockin MEFs was assessed for phosphorylation of Nictide peptide substrate in the absence or presence of MLi-2 (1 μM). IgG controls were also included
where LRRK2 immunoprecipitating antibody was replaced by pre-immune IgG. Western blots below show the levels of immunoprecipitated LRRK2 used for the kinase assays and LRRK2 levels in
pre-immune lysates. Results are means +− S.D. (n = 3). (C) Littermate WT and kinase-inactive LRRK2[D2017A] knockin MEFs were treated with or without 1 μM GSK2578215A for 1 h. Cell lysates
were prepared and Rab10 phosphorylation was analysed by a Phos-tag assay (top panel). Control immunoblots were done on normal gels with the indicated antibodies. (D) As in (C) except littermate
WT and LRRK2 KO MEFs were used. (E) Littermate WT and MLi-2-resistant LRRK2[A2016T] knockin MEFs were treated with the indicated concentrations of MLi-2 for 1 h in duplicate. Cell lysates
were prepared and Rab10 phosphorylation was analysed by a Phos-tag assay (top panel). Control immunoblots were done on normal gels with the indicated antibodies. Bands corresponding to
phosphorylated and non-phosphorylated Rab10 were marked with open () and closed () circles respectively. Similar results were obtained in at least two separate experiments.
∼70% of Rab10 was phosphorylated and the phosphorylation-
induced mobility was blocked by mutation of the LRRK2
phosphorylation site (Thr73 to alanine) or by treatment of cells
with MLi-2 LRRK2 inhibitor (Figure 1B).
Use of the Phos-tag approach to assess LRRK2-mediated
phosphorylation of endogenous Rab10 in MEFs
We tested whether the Phos-tag approach could be used
to assess LRRK2 phosphorylation of endogenous Rab10
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Figure 3 Dose-dependent inhibition of Rab10 phosphorylation in MEFs analysed by Phos-tag assay
WT MEFs were treated with the indicated concentrations of (A) GSK2578215A or (B) HG-10-102-01 for 1 h in duplicate. Cell lysates were prepared and Rab10 phosphorylation was analysed by a
Phos-tag assay (top panel). Control immunoblots were done on normal gels with the indicated antibodies. (C and D) As in (A) and (B) except LRRK2[G2019S]GSK knockin MEFs were used. (E) As
in (C) and (D) except MLi-2 was used. Bands corresponding to phosphorylated and non-phosphorylated Rab10 were marked with open () and closed () circles respectively. Similar results were
obtained in at least two separate experiments.
in MEFs. The Rab10 antibody used for these studies
was selective as it detected endogenous Rab10 in WT,
but not in clustered regularly interspaced short palindromic
repeats (CRISPR)/CRISPR-associated 9 (Cas9) Rab10 knockout
A549 cells (Supplementary Figure S1). Phos-tag analysis of
Rab10 derived from WT MEFs revealed that the bulk of
Rab10 was in the unphosphorylated form; nevertheless, a
significant minor phosphorylated Rab10 species was observed
(Figure 2A). Treatment of WT MEFs with structurally
diverse LRRK2 inhibitors (GSK2578215A, HG-10-102-01 and
MLi-2) prevented Rab10 phosphorylation as judged by loss of
the phosphorylated slower migrating Rab10 species (Figure 2A).
We next analysed Rab10 phosphorylation in MEFs derived
from a novel kinase-inactive LRRK2[D2017A] knockin mouse
model, described here for the first time. LRRK2 isolated
from the LRRK2[D2017A] knockin MEFs is expressed at
slightly elevated levels compared with that in littermate WT
cells (Figure 2B). Kinase activity measurements following
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Figure 4 Time-course experiments to compare phosphorylation of endogenous LRRK2 Ser935 and endogenous Rab10 in MEFs analysed by Phos-tag assay
WT MEFs were treated with (A) 1 μM GSK2578215A, (B) 3 μM HG-10-102-01 or (C) 10 nM MLi-2. Cell lysates were prepared at the indicated time points and Rab10 phosphorylation was analysed by
a Phos-tag assay (top panel). Control immunoblots were done on normal gels with the indicated antibodies. (D) LRRK2[G2019S]GSK knockin MEFs were treated with 1 μM GSK2578215A. Cell lysates
were prepared at the indicated time points and Rab10 phosphorylation was analysed by a Phos-tag assay. Control immunoblots were done on normal gels with the indicated antibodies. Endogenous
LRRK2 was also immunoprecipitated from cell lysates and blotted with the anti-pS1292 or total LRRK2 antibody (top panel). Bands corresponding to phosphorylated and non-phosphorylated Rab10
were marked with open () and closed () circles respectively. Similar results were obtained in at least two separate experiments.
LRRK2 immunoprecipitation confirmed that LRRK2 in
the LRRK2[D2017A] knockin cells is devoid of kinase
activity (Figure 2B). Phos-tag analysis revealed that Rab10
phosphorylation was strikingly absent from LRRK2[D2017A]
knockin MEFs (Figure 2C). We also observed that Rab10 was
also not phosphorylated in LRRK2 knockout MEFs (Figure 2D).
Phos-tag analysis permitted detection of MLi-2 inhibition
of Rab10 phosphorylation in WT and previously described
MLi-2 inhibitor resistant LRRK2[A2016T] knockin MEFs
[13] (Figure 2E). Doses of 3–10 nM MLi-2 suppressed
Rab10 phosphorylation in WT MEFs, but concentrations of
100 nM were required to equivalently reduce phosphorylation
in LRRK2[A2016T] knockin cells (Figure 2E). MLi-2 induced
dephosphorylation of the LRRK2 Ser935 biomarker site [28],
paralleled Rab dephosphorylation in the WT as well as the
inhibitor-resistant LRRK2[A2016T] knockin MEFs (Figure 2E).
Two other structurally diverse GSK2578215A [29], HG-10-102-
01 [30] LRRK2 inhibitors induced a dose-dependent inhibition
of Rab10 phosphorylation in WT MEFs (Figures 3A and 3B),
with suppression of Rab10 phosphorylation coinciding with loss
of LRRK2 Ser935 phosphorylation. LRRK2[G2019S]GSK knockin
MEFs were treated with the LRRK2 inhibitors (Figures 3C–3E),
showing inhibition of Rab10 phosphorylation and loss of LRRK2
Ser935 phosphorylation at a similar dose to that required in WT
MEFs (Figures 2E, 3A and 3B).
LRRK2 inhibitors induce more rapid dephosphorylation of Rab10
than kinase biomarker residues (Ser935 and Ser1292)
We next compared the rate at which Rab10 and LRRK2 Ser935
are dephosphorylated following treatment of WT MEFs with
structurally diverse kinase inhibitors. This revealed that Rab10
was rapidly dephosphorylated within 1–2 min following treatment
with 1 μM GSK2578215A (Figure 4A) or 3 μM HG-10-102-
01 (Figure 4B) and 5–10 min with 10 nM MLi-2 (Figure 4C).
In contrast, dephosphorylation of LRRK2 Ser935 was markedly
slower requiring 40–80 min (Figures 4A–4C). Previous work
revealed that the autophosphorylation of LRRK2 at Ser1292 can
also be deployed as a read out for LRRK2 kinase activity and
that phosphorylation of this residue is enhanced by pathogenic
mutations including G2019S [37]. To investigate the rate at
which Ser1292 is dephosphorylated, we treated LRRK2[G2019S]
knockin MEFs (in which Ser1292 is more readily detected than
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Figure 5 Phosphorylation of endogenous Rab10 in mouse lung and spleen-derived B-cells analysed by Phos-tag assay
(A) Lung tissues were collected from two littermate WT and two kinase-inactive LRRK2[D2017A] knockin mice. Tissue lysates were prepared and Rab10 phosphorylation was analysed by a Phos-tag
assay (top panel). Control immunoblots were done on normal gels with the indicated antibodies. (B) Littermate WT and MLi-2-resistant LRRK2[A2016T] mice were subcutaneously injected with the
indicated doses of MLi-2 and treated for 1 h (two mice for each dose). Lung tissues were collected and Rab10 phosphorylation was analysed by a Phos-tag assay (top panel). Control immunoblots
were done on normal gels with the indicated antibodies. (C) B-cells were isolated from eight WT mouse spleens and treated with or without 50 nM MLi-2 for 1 h (four replicates for each condition). Cell
lysates were prepared and Rab10 phosphorylation was analysed by a Phos-tag assay (top panel). Control immunoblots were done on normal gels with the indicated antibodies. Bands corresponding
to phosphorylated and non-phosphorylated Rab10 were marked with open () and closed () circles respectively. Similar results were obtained in at least two separate experiments.
in WT MEFs) with 1 μM GSK2578215A for various time
points. Ser1292 phosphorylation was analysed employing a Ser1292
phospho-specific antibody following immunoprecipitation of
LRRK2. These studies revealed that dephosphorylation of Ser1292
occurred on a longer time course more similar to that of Ser935
requiring 80–160 min to attain maximal dephosphorylation. As
observed in WT MEFs (Figure 4A), GSK2578215A induced rapid
dephosphorylation of Rab10 within 1–2 min in LRRK2[G2019S]
knockin MEFs (Figure 4D).
Use of the Phos-tag approach to assess LRRK2-mediated
phosphorylation of endogenous Rab10 in mouse lung and spleen
derived B-cells
We next analysed Rab10 phosphorylation in littermate WT and
kinase-inactive LRRK2[D2017A] knockin mouse lung tissue.
This revealed that phosphorylation of Rab10 was readily
observed in WT but not in the kinase-inactive LRRK2[D2017A]
knockin lung (Figure 5A). Injection of WT mice with doses of
1–3 mg/kg MLi-2 blocked Rab10 phosphorylation, whereas doses
of 10 mg/kg MLi-2 were needed to induce equivalent blockade
in LRRK2[A2016T] inhibitor-resistant lung (Figure 5B). MLi-
2 induced dephosphorylation of LRRK2 Ser935 paralleled Rab
dephosphorylation, with significantly higher doses of MLi-2
required to induce equivalent Ser935 and Rab10 dephosphorylation
in LRRK2[A2016T] lung compared with WT (Figure 5B).
Phosphorylated Rab10 was also detected in splenic B-cells
derived from WT mice, which was lost following incubation of
B-cells with MLi-2 in RPMI 1640 medium for 60 min prior to
cell lysis (Figure 5C).
Use of the Phos-tag approach to assess the impact of LRRK2
pathogenic mutations
We next employed the Phos-tag approach to assess the
impact of homozygous LRRK2[R1441G] (Figure 6A) and
LRRK2[G2019S]GSK (Figure 6B) knockin mutations on LRRK2
Rab10 phosphorylation in MEFs. Compared with WT controls,
the LRRK2[R1441G] knockin enhanced Rab10 phosphorylation
∼3–4-fold (Figure 6A) and the G2019S mutation enhanced
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Figure 6 Phosphorylation of endogenous Rab10 in MEFs harbouring
pathogenic mutations analysed by Phos-tag assay
(A) Littermate WT and pathogenic LRRK2[R1441G] knockin MEFs were treated with or without
1 μM GSK2578215A for 1 h. Cell lysates were prepared and Rab10 phosphorylation was
analysed by a Phos-tag assay (top panel). Control immunoblots were done on normal gels with
the indicated antibodies. (B) As in (A) except littermate WT and pathogenic LRRK2[G2019S]GSK
knockin MEFs were used. Bands corresponding to phosphorylated and non-phosphorylated
Rab10 were marked with open () and closed () circles respectively. Similar results were
obtained in at least two separate experiments.
phosphorylation ∼2-fold (Figure 6B). In both R1441G and
G2019S knockin MEFs, LRRK2 inhibitors suppressed Rab10
phosphorylation (Figure 6). Consistent with a previous report
[12], the R1441G knockin mutation markedly inhibited basal
levels of LRRK2 Ser935 phosphorylation (Figure 6B).
We next analysed Rab10 phosphorylation in littermate WT
and LRRK2[R1441G] knockin mouse lung tissue. This revealed
that phosphorylation of Rab10 was markedly elevated in
LRRK2[R1441G] knockin lung compared with WT (Figure 7A).
Injection of 3 mg/kg MLi-2 for 60 min blocked Rab10
phosphorylation in both WT and LRRK2[R1441G] knockin
mouse lung (Figure 7B).
Use of the Phos-tag approach to assess the impact of S910A/S935A
mutations
There is significant interest in understanding the roles that LRRK2
phosphorylation at LRRK2 Ser910 and Ser935 residues plays in
controlling LRRK2 activity, as these phosphorylations regulate
interaction of LRRK2 with 14-3-3 proteins and are also sensitive
to LRRK2 inhibitors [12,28]. To better understand the role of
Ser910 and Ser935 phosphorylations, we generated homozygous
LRRK2[S910A + S935A] knockin MEFs. Immunoblot analysis
confirmed that the LRRK2[S910A + S935A] mutant kinase
was expressed at the same level as LRRK2 derived
from littermate WT cells (Figure 8A). Moreover, following
immunoprecipitation, the LRRK2[S910A + S935A] mutant was
capable of phosphorylating recombinant Rab8A in vitro to a
similar extent as the WT LRRK2 (Figure 8B). Rab8A rather than
Rab10 was used for these experiments as rates of phosphorylation
of Rab8A by immunoprecipitated endogenous LRRK2 was much
higher and could be more robustly quantified than with Rab10.
Strikingly, we observed that endogenous Rab10 phosphorylation
was markedly reduced in the LRRK2[S910A + S935A]
knockin MEFs compared with littermate-derived WT cells
(Figure 8C).
DISCUSSION
Here we show that the Rab10 Phos-tag assay can readily be
used to assess LRRK2-mediated phosphorylation of endogenous
Rab10 in MEFs, mouse lung, mouse spleen-derived B-cells.
We expect that the Rab10 Phos-tag assay will work in other
cell lines in which LRRK2 and Rab10 are well expressed.
The Rab10 Phos-tag assay is straightforward, necessitating
only SDS/polyacrylamide gel and immunoblotting apparatus
and moderate amounts of cell extracts (10–45 μg of protein).
Moreover, the two key reagents required for the assay, namely
the anti-Rab10 monoclonal antibody and Phos-tag acrylamide are
both commercially available. To reduce assay costs, we undertook
chemical synthesis of the Phos-tag acrylamide reagent. It should
also be noted that Phos-tag reagent requires Mn2 + ions in order
to interact with phosphate groups [25–27]. We have also found
that the Phos-tag acrylamide reagent can undergo polymerization
following long-term storage which results in reduced separation
of dephosphorylated and LRRK2-phosphorylated Rab10. The
optimal conditions we have found to store Phos-tag acrylamide
is 5 mM in aqueous solution at 4 ◦C in black tubes that block out
light as the reagent is light-sensitive. We would also recommend
that purity of Phos-tag acrylamide be assessed by HPLC analysis
periodically. We would also recommend that if samples to be
analysed and/or the SDS sample buffer contain EDTA, an excess
of MnCl2 over EDTA is added to the sample prior to loading the
samples on to the Phos-tag gel. A single researcher could readily
analyse a few dozen of samples per day using the Rab10 Phos-tag
assay.
The finding that diverse LRRK2 inhibitors, kinase-inactivating
LRRK2[D2017A] knockin mutation as well as LRRK2 knockout,
ablate all detectable phosphorylation of Rab10, strongly suggests
that LRRK2 is the major kinase that phosphorylates Rab10
at least in MEFs and lung tissue that we have analysed.
The finding that LRRK2[A2016T] inhibitor-resistant knockin
increases the dose of LRRK2 inhibitor required to reduced
Rab10 phosphorylation in both MEFs and mouse lung provides
a fundamental demonstration that LRRK2 is the major kinase
controlling Rab10 phosphorylation in MEFs.
Another advantage of the Phos-tag method is that it allows
assessment of stoichiometry of phosphorylation. In MEFs and
lung tissue that we have analysed, the data indicate that only
a small fraction of Rab10 is phosphorylated at steady state.
This probably accounts for why it was challenging to identify
phosphorylated species of Rab10 by mass spectrometry, as
such a low proportion of the Rab protein is phosphorylated
by LRRK2 in vivo. However, the low basal levels of LRRK2-
phosphorylated Rab10 may make it easier to monitor the
impact of activating LRRK2 pathogenic mutations have on
enhancing Rab10 phosphorylation (Figure 6 and 7). We have also
examined total brain and kidney tissue extracts to see whether
c© 2016 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution Licence 4.0 (CC BY).
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Figure 7 Phosphorylation of endogenous Rab10 in mouse lung harbouring pathogenic mutations analysed by Phos-tag assay
Littermate WT and pathogenic LRRK2[R1441G] knockin mice were subcutaneously injected with vehicle only or MLi-2 at 3 mg/kg and treated for 1 h (three mice for vehicle control and five mice for
MLi-2). Lung tissues were collected and Rab10 phosphorylation was analysed by a Phos-tag assay (top panel). Control immunoblots were done on normal gels with the indicated antibodies. (A)
Side-by-side comparison of WT and LRRK2[R1441G] knockin lungs on a same gel. (B) Side-by-side comparison of lungs injected with vehicle or MLi-2 on a same gel. Bands corresponding to
phosphorylated and non-phosphorylated Rab10 were marked with open () and closed () circles respectively. Similar results were obtained in at least two separate experiments.
we could detect LRRK2-mediated phosphorylation of Rab10,
but failed to observe significant Rab10 phosphorylation using
the described Phos-tag assays under conditions where LRRK2
phosphorylation of Rab10 in lung and spleen was observed.
Further work is warranted to develop methodology to assess
LRRK2 phosphorylation of Rab10 in brain and kidney.
In the future it will be interesting to explore whether it is
possible to observe LRRK2-dependent phosphorylation of Rab
proteins using the Phos-tag approach in human derived cells such
as fibroblast, peripheral blood mononuclear cells (PBMCs) or
other blood cells, as well as bodily fluids such as in cerebrospinal
fluid. It will also be important to explore whether elevated Rab
protein phosphorylation can be observed in Parkinson’s disease
patients who are carriers of LRRK2 mutations and whether a
subgroup of Parkinson’s disease patients with idiopathic disease
also display elevated Rab phosphorylation. For the benefit of
future clinical trials of LRRK2 inhibitors, it would be desirable
to determine whether target engagement of LRRK2 inhibitors
could be demonstrated by monitoring the effect these compounds
have on Rab protein phosphorylation in human blood cells. It will
also be intriguing to investigate whether the Rab Phos-tag assay
can be used to detect LRRK2-phosphorylated Rab proteins in
human urinary exosomes that contain LRRK2 [38]. Recent studies
have reported elevated phosphorylation of LRRK2 at its Ser1292
autophosphorylation site [37] in urine exosomes and concluded
that this can predict Parkinsonian phenotypes in G2019S LRRK2
subjects [39].
There has been a lot of interest in studying the roles of the
LRRK2 Ser910 and Ser935 phosphorylation sites, as these mediate
14-3-3 binding and become dephosphorylated when cells are
exposed to LRRK2 inhibitors [12,28]. Most of the data suggest
that Ser910 and Ser935 are likely to be phosphorylated by kinases
distinct to LRRK2 [12,28]. Although several candidates for the
LRRK2 Ser910 and Ser935 kinase(s) have been proposed [40–
42], further studies are required to pinpoint these kinase(s) and
characterize how inhibition of LRRK2 leads to dephosphorylation
of these residues. Consistent with the notion that an LRRK2-
distinct kinase phosphorylates Ser935, we observe that Ser935 is still
phosphorylated in the LRRK2[D2017A] kinase-inactive MEFs
(Figure 2C) and lungs (Figure 5A). However, following MLi-2
administration, in contrast with wild type situation where Ser935
becomes dephosphorylated, in the LRRK2[D2017A] knockin
MEFs, Ser935 is not dephosphorylated (Figure 2C). This is
consistent with a model in which the LRRK2 Ser935 kinase
is uncoupled from LRRK2 in the LRRK2[D2017A] knockin
MEFs. The finding that treatment of cells with LRRK2 inhibitors
induces more rapid dephosphorylation of Rab10 (1–2 min with
GSK2578215A and HG-10-102-01) than Ser935 (40–80 min,
Figures 4A–4C), is consistent with the regulation of Rab10
being directly mediated by LRRK2, whereas phosphorylation
of Ser935 is indirectly controlled. The rapid dephosphorylation
Rab10 that is observed following suppression of LRRK2 kinase
activity may indicate that the phosphatase that acts on Rab10 is
highly active and/or the Thr73 residue is exposed and accessible
to the phosphatase. In contrast, dephosphorylation of the Ser1292
autophosphorylation site of LRRK2 was significantly slower
than Rab10, necessitating 40–80 min (Figure 4D). This slower
dephosphorylation might result if the phosphatase that targets
Ser1292 had low activity and/or access of phosphorylated Ser1292 to
the protein phosphatase was hindered.
The finding that the LRRK2[S910A + S935A] knockin
mutation suppresses phosphorylation of Rab10 in MEFs, provides
evidence for a functional role of Ser910 and Ser935 phosphorylation
in enabling LRRK2 to optimally phosphorylate Rab GTPases.
More work is needed to unravel this mechanism. One possibility
is that this is mediated through localization of LRRK2. Previous
work in a HEK-293 cell overexpression system suggested that the
LRRK2[S910A + S935A] mutant was assembled into inclusion-
like bodies very different from the WT LRRK2 that was diffusely
localized throughout the cytosol. As functional Rab proteins
are largely localized on membranes, perhaps LRRK2 Ser910 and
Ser935 phosphorylation and 14-3-3 binding facilitate recruitment
of LRRK2 on to membranes where it can phosphorylate Rab
proteins.
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